|
Per electrophysiology examination of incision on (b)(6) 2017 site suggestive potential seroma versus hematoma.Upon physical evaluation, it is soft to the touch, without surrounding erythema, or increased pain from post procedural baseline.Additionally, there has been no reported fevers or chills, and white blood cell count has remained stable.Doppler scan has ruled out deep vein thrombosis.Patient reports no missed dosing of keflex post procedure.Patient was recommended to increase antibiotic regimen of keflex 500mg tid from 5 to 7 days.The instructions for use for the cangaroo ecm envelope lists 'seroma' under potential complications associated with the use of the device.The device remains implanted and no further events have been reported.A review of manufacturing lot history record shows that the reported lot was released to distribution on 1/19/2017 having met all manufacturing and quality release requirements including product sterility testing.There were no manufacturing deviations or non-conformances associated with the production of this lot.
|
|
It was reported that a (b)(6) year old female with a history of malignancy and pocket re-entry (within 2 weeks of initial implant), left bundle branch block and chronic obstructive pulmonary disease had a dual chamber pacemaker implanted on (b)(6) 2017 using a cormatrix cangaroo ecm envelope (cmcv-009-med lot # m16n1322), hydrated with vancomycin and gentamycin.Patient required an rv lead revision due to dislodgement on (b)(6) 2017.On (b)(6) 2017 subject presented at the emergency department and was diagnosed with seroma/hematoma at the pacemaker site.This site investigator determined that the event was possibly related to cangaroo ecm and probably related to the procedure.The probable cause of the event was listed as, "seroma/hematoma at pacemaker site".
|